IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Of 18F MEL050 Using PET/CT in Metastatic Melanoma (MEL050)
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2012 by Cooperative Research Centre for Biomedical Imaging Development.
Recruitment status was: Active, not recruiting
Recruitment status was: Active, not recruiting
Sponsor:
Cooperative Research Centre for Biomedical Imaging Development
Information provided by (Responsible Party):
Cooperative Research Centre for Biomedical Imaging Development
ClinicalTrials.gov Identifier:
NCT01620749
First received: May 27, 2012
Last updated: June 14, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F MEL050 for finding sites of melanoma.
| Condition | Intervention | Phase |
|---|---|---|
| Metastatic Melanoma | Radiation: 18F MEL050 | Early Phase 1 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic |
| Official Title: | A Phase 0 Exploratory Microdosing Study of 6-18fluoro-N-[2-(Diethylamino)Ethyl]Pyridine-3-carboxamide (18F MEL050) Using PET/CT in Patients With Metastatic Melanoma |
Resource links provided by NLM:
Further study details as provided by Cooperative Research Centre for Biomedical Imaging Development:
Primary Outcome Measures:
- Safety of 18F MEL050 administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F MEL050 administration. [ Time Frame: Up to 28 days following 18F MEL050 administration (+/- 7 days) ]
Secondary Outcome Measures:
- Percentage of injected 18F MEL050 dose in organs of interest. [ Time Frame: 10, 30, 60 and 120 minutes post 18F MEL050 administration ]
- Percentage of unmetabolized 18F MEL050 in plasma and urine after radiotracer administration. [ Time Frame: 60, 120 and 180 minutes post 18F MEL050 administration. ]
- Absorbed organ doses and whole body dose expressed as milliSv/200MBq administered dose. [ Time Frame: 10, 30, 60 and 120 minutes post 18F MEL050 administration ]
| Enrollment: | 12 |
| Study Start Date: | June 2010 |
| Estimated Study Completion Date: | December 2012 |
| Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: MEL050 |
Radiation: 18F MEL050
Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent obtained prior to any protocol-specific procedures
- Male and female patients with histologically confirmed melanoma
- At least one site of metastatic disease, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care
- Age >/= 18 years
- Life expectancy >/=3 months
- ECOG performance score of 0-2
Exclusion Criteria:
- Pregnant or breastfeeding females
- Systemic anti-melanoma therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F MEL050 PET/CT scan
- Patients whose clinical care may be compromised because of the delay resulting from performance of the 18F MEL050 PET/CT scan
- Patients whose only metastatic lesion is in the Central Nervous System
- Patients with urinary incontinence or patients who cannot comfortably hold their urine for more than 90 minutes
- Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
- Patients unwilling or unable to comply with protocol and patients with a history of non compliance or inability to grant informed consent.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01620749
Please refer to this study by its ClinicalTrials.gov identifier: NCT01620749
Locations
| Australia, Victoria | |
| Peter MacCallum Cancer Centre | |
| East Melbourne, Victoria, Australia, 3002 | |
Sponsors and Collaborators
Cooperative Research Centre for Biomedical Imaging Development
Investigators
| Principal Investigator: | Grant McArthur | Peter MacCallum Cancer Centre, Australia |
More Information
| Responsible Party: | Cooperative Research Centre for Biomedical Imaging Development |
| ClinicalTrials.gov Identifier: | NCT01620749 History of Changes |
| Other Study ID Numbers: |
10/11 |
| Study First Received: | May 27, 2012 |
| Last Updated: | June 14, 2012 |
Keywords provided by Cooperative Research Centre for Biomedical Imaging Development:
|
melanoma metastatic diagnosis |
Additional relevant MeSH terms:
|
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas |
ClinicalTrials.gov processed this record on September 19, 2017